Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea · Delayed Price · Currency is KRW 5,980.00
-20.00 (-0.33%)
At close: Feb 13, 2026
Sinil Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 11,311 | 14,301 | 13,641 | 12,157 | 6,679 | 7,544 |
Depreciation & Amortization | 7,228 | 5,607 | 5,361 | 4,432 | 4,536 | 4,432 |
Loss (Gain) From Sale of Assets | 0.09 | -3.72 | 641.55 | -221.3 | -14 | -13.42 |
Asset Writedown & Restructuring Costs | -31 | -31 | 7 | 92.08 | -14.5 | -97.5 |
Loss (Gain) From Sale of Investments | 26.81 | 26.81 | 532.61 | 373.44 | -115.48 | 11.37 |
Provision & Write-off of Bad Debts | -8.2 | 797.59 | 446.86 | 409.12 | 160.62 | 472.81 |
Other Operating Activities | 225.85 | 3,161 | -408.83 | 2,903 | 2,102 | 565.25 |
Change in Accounts Receivable | 428.4 | 855.22 | 1,095 | -3,247 | 161.49 | 147.62 |
Change in Inventory | -3,436 | -369.61 | -2,304 | -3,487 | 236.85 | -1,865 |
Change in Accounts Payable | 497.62 | -113.72 | -1,271 | 1,840 | 1,210 | -288.05 |
Change in Other Net Operating Assets | -3,053 | -1,541 | -2,587 | -1,563 | -3,779 | 152.7 |
Operating Cash Flow | 13,267 | 22,689 | 15,154 | 13,688 | 11,163 | 11,062 |
Operating Cash Flow Growth | -49.70% | 49.72% | 10.72% | 22.61% | 0.92% | -10.11% |
Capital Expenditures | -5,310 | -10,362 | -13,604 | -10,351 | -3,343 | -8,801 |
Sale of Property, Plant & Equipment | 18.1 | 74.92 | 122.76 | 316.6 | 145.68 | 28.82 |
Sale (Purchase) of Intangibles | -162.7 | -94.64 | -57 | -27.5 | -285.65 | -101.55 |
Investment in Securities | -3,943 | -13,268 | 2,510 | -4,880 | -3,103 | 177.8 |
Other Investing Activities | 193.97 | 176.53 | -291.6 | 62.27 | -95 | 29.95 |
Investing Cash Flow | -9,203 | -23,473 | -11,319 | -14,880 | -6,665 | -8,609 |
Short-Term Debt Issued | - | - | 22,578 | - | - | - |
Total Debt Issued | - | - | 22,578 | - | - | - |
Short-Term Debt Repaid | - | - | -22,578 | - | - | - |
Long-Term Debt Repaid | - | -147.23 | -154.09 | -133.75 | -127.98 | -122.81 |
Total Debt Repaid | -188.63 | -147.23 | -22,732 | -133.75 | -127.98 | -122.81 |
Net Debt Issued (Repaid) | -188.63 | -147.23 | -154.09 | -133.75 | -127.98 | -122.81 |
Repurchase of Common Stock | - | - | -73.39 | -104.49 | -168.43 | -6.26 |
Dividends Paid | -2,196 | -1,965 | -1,112 | -1,081 | -1,051 | -1,126 |
Other Financing Activities | 198 | -24 | 92 | - | -0 | - |
Financing Cash Flow | -2,187 | -2,136 | -1,248 | -1,319 | -1,347 | -1,255 |
Foreign Exchange Rate Adjustments | 26.5 | 44.83 | -11.37 | 114.94 | 25.44 | -9.82 |
Miscellaneous Cash Flow Adjustments | - | - | -0 | - | - | - |
Net Cash Flow | 1,903 | -2,876 | 2,576 | -2,396 | 3,176 | 1,188 |
Free Cash Flow | 7,957 | 12,327 | 1,551 | 3,336 | 7,820 | 2,261 |
Free Cash Flow Growth | -64.47% | 694.85% | -53.52% | -57.34% | 245.93% | -12.24% |
Free Cash Flow Margin | 9.83% | 13.78% | 1.74% | 4.17% | 12.66% | 3.68% |
Free Cash Flow Per Share | 688.36 | 1066.39 | 134.13 | 299.94 | 695.63 | 200.87 |
Cash Interest Paid | 21.76 | 26.97 | 26.13 | 6.05 | 9.72 | 13.24 |
Cash Income Tax Paid | 2,825 | 468.26 | 3,081 | 772.84 | 1,113 | 1,721 |
Levered Free Cash Flow | 5,084 | 8,588 | -2,857 | 148.73 | 8,141 | -2,130 |
Unlevered Free Cash Flow | 5,098 | 8,605 | -2,840 | 152.52 | 8,147 | -2,122 |
Change in Working Capital | -5,486 | -1,169 | -5,067 | -6,457 | -2,170 | -1,853 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.